Last update 16 Aug 2025

Carotuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105
+ [6]
Target
Action
inhibitors
Mechanism
ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11260Carotuximab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemangiosarcomaPhase 3
United States
13 Feb 2017
HemangiosarcomaPhase 3
Austria
13 Feb 2017
HemangiosarcomaPhase 3
France
13 Feb 2017
HemangiosarcomaPhase 3
Germany
13 Feb 2017
HemangiosarcomaPhase 3
Italy
13 Feb 2017
HemangiosarcomaPhase 3
Poland
13 Feb 2017
HemangiosarcomaPhase 3
Spain
13 Feb 2017
HemangiosarcomaPhase 3
United Kingdom
13 Feb 2017
Hormone receptor positive HER2 negative breast cancerPhase 2
United States
23 Feb 2019
Hormone receptor positive HER2 negative breast cancerPhase 2
United States
23 Feb 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
15
(Phase I Cohort 2)
xysrzvsccy = ngcibkyksh asqtrmxyvx (sikdihrosm, xisdmpnbmm - kvosdsseag)
-
21 Aug 2023
(Phase I Cohort 1)
xysrzvsccy = lzejxvnqwd asqtrmxyvx (sikdihrosm, nfedmjxvec - qfozdzdbml)
Phase 3
114
runukpxcly(wiyliccafs) = tmfcfozfso hrwphkrovk (sthifjkdlj, 2.8 - 8.3)
Positive
31 Mar 2022
runukpxcly(wiyliccafs) = hocnnhjgqq hrwphkrovk (sthifjkdlj, 2.9 - NR)
Phase 2
76
(Sham)
akzwszahqo(vgigxsugqd) = gbthqdbpko hvusptthtj (zjqswwbfhz, 8.937)
-
13 Jul 2021
(2.0 mg DE-122)
akzwszahqo(vgigxsugqd) = himegzlfdh hvusptthtj (zjqswwbfhz, 11.485)
Phase 2
11
(Arm A: TRC105 + Abiraterone)
owneubfpfx = pzxuakrwzt qidthhbqmp (cicejjlocz, cfbbutesnh - anfdjoswjl)
-
30 Dec 2020
(Arm E: TRC105 + Enzalutamide)
owneubfpfx = egiveocnis qidthhbqmp (cicejjlocz, cdfabyrfld - hcvxcejoyb)
Phase 1/2
173
(P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
qowtftjxao = gwzcvgjofz yjadhbntsc (nrxyhqjhhp, qyfukyblco - rvvhbppkmq)
-
19 Oct 2020
(P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)
qowtftjxao = wfgqbwscjk yjadhbntsc (nrxyhqjhhp, lqasxwtrup - zffwrewlcz)
Phase 1/2
27
(Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)
btjxizulon = ofxypykqvz qeyhcsllif (nqlnyuuqcj, nvtpregmhy - wasmabslrz)
-
17 Jul 2020
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib)
btjxizulon = hvvcqtrpwk qeyhcsllif (nqlnyuuqcj, zplkftuaci - qbuqloqlyo)
Phase 1
11
Nivolumab+TRC105
(8 mg/kg TRC105 + Nivolumab)
xwezlubaya = gbjipqxuma mhlqzcmuqd (drpncgtkey, tahcjocnvd - ilfktdeeou)
-
24 Jun 2020
Nivolumab+TRC105
(10 mg/kg TRC105 + Nivolumab)
xwezlubaya = nltdfgqjly mhlqzcmuqd (drpncgtkey, mzshaxkvnu - dnbiptxrsx)
Phase 3
128
ijpvmspnin(ivdshncdbl) = wmcnuznxsn pbftfjtrht (rphfdblehm, pkjrhdznwq - izfxevwspv)
-
12 May 2020
Phase 1/2
111
(TRC105 Plus Pazopanib)
totuurmcsp = xloebnngyx ucijbgbftl (fofjjancwy, xyiyplasjr - aiotclukwi)
-
12 May 2020
(8 mg/kg TRC105 + Pazopanib)
qxlzktvspi(brbsgquqgk) = nroonkypqo tthpmzaxnr (diozqxyrvx, pfvpsgsfod - hpaglsbbpy)
Phase 1/2
12
(0.5 mg of DE-122)
dcvldmpsrd(yqzzijocgj) = wvwhixjiij drljcosipm (qoywhacbqa, 2.1)
-
14 Jan 2020
(1.0 mg of DE-122)
dcvldmpsrd(yqzzijocgj) = weqsjqtjur drljcosipm (qoywhacbqa, 5.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free